Acadia (ACHC) Q4 2025 earnings review
Revenue Holds Up, But One-Offs and Liability Costs Crush Profitability
Acadia Healthcare reported stable top-line growth of 6.1% in Q4, beating its own implied guidance. However, the volume recovery masks a severely deteriorating bottom line. A massive $996.2M non-cash goodwill impairment and $147.5M in legal settlements completely wiped out GAAP earnings. Even on an adjusted basis, EBITDA plunged 35% year-over-year, heavily burdened by a $52.7M adjustment to professional and general liability (PLGL) reserves. The company is pivoting sharply to capital discipline in 2026, slashing CapEx by over half to protect cash flow amidst gathering Medicaid policy headwinds.
🐂 Bull Case
Acadia added 1,089 beds in FY25. This capacity influx drove a 10% YoY revenue increase in the Acute Inpatient Psychiatric segment in Q4. If operational friction eases, this expanded footprint provides a long runway for future volume.
Management is sharply Reversing its capital allocation strategy. By cutting 2026 expansion and maintenance CapEx to a midpoint of $267.5M (down from $571M in FY25), Acadia is prioritizing free cash flow generation over unrestrained growth.
🐻 Bear Case
The $52.7M PLGL reserve adjustment in Q4 underscores a structural profitability headwind. Total PLGL expenses hit $115M in FY25 (more than double FY24). This implies higher underlying risks and operational costs across the facility network.
Guidance incorporates a $25-$30M negative hit to Adjusted EBITDA in 2026 due to New York Medicaid policy changes restricting out-of-state care. Combined with the loss of a non-recurring $28.5M Tennessee benefit from 2025, policy risk is actively degrading earnings power.
⚖️ Verdict: 🔴
Bearish. The company is actively cleaning up its balance sheet (impairments, legal settlements), but core operating profitability is Decelerating. Management's narrative of 'improved volume' is directly contradicted by anemic 0-1% same-facility volume guidance for 2026.
Key Themes
Professional Liability Expenses Crippling Margins
Professional and general liability (PLGL) expense is Accelerating at an alarming rate. Acadia absorbed a $52.7M true-up in Q4 alone, pushing total FY25 PLGL costs to $115M (up from $54M in FY24). The balance sheet reserve has doubled to $153M. This suggests systemic risk and increased claims across the facility portfolio, directly degrading the company's operating leverage.
Stagnating Same-Facility Volume Outlook Contradicts Narrative
Despite the CEO citing 'improved volume growth' in the Q4 release, FY26 guidance projects Decelerating same-facility volume growth of just 0% to 1%. This reflects deep underlying pressure. The anemic growth is heavily burdened by an approximate 350 basis point headwind from New York Medicaid policy changes limiting out-of-state specialty care. The data does not support the bullish volume narrative.
Macro: Medicaid Policy Uncertainty Biting Real Earnings
State-level Medicaid shifts are proving to be a double-edged sword. In 2025, Acadia benefited from a one-time $28.5M Tennessee supplemental payment. In 2026, they face a Reversing dynamic: losing that Tennessee benefit while simultaneously absorbing a $25-$30M penalty from New York policy changes. Management previously noted vulnerability to the 'One Big Beautiful Bill Act' (OBBBA), and these state-level adjustments prove that regulatory shifts represent a material threat to margins.
Acute Inpatient Capacity Ramping Up
Acute Inpatient Psychiatric Facilities remain the core growth engine, with Q4 revenue Accelerating to 10% YoY growth ($451M). Volumes increased 6%, directly fueled by the 1,089 new licensed beds brought online during FY25. As these new beds transition out of their 'startup loss' phase, they should become the primary driver of top-line durability.
Pivoting from Growth CapEx to Cash Flow Generation
After years of aggressive physical expansion, Acadia is Reversing its capital allocation strategy. FY26 guidance limits total CapEx to $255-$280M (down sharply from $571M in FY25 and $690M in FY24). This disciplined approach restricts new bed additions to 400-600 (down from 1,089) but is explicitly designed to unlock free cash flow and support the heavily leveraged balance sheet.
Specialty Treatment Segment Remains a Chronic Laggard
The Specialty Treatment segment continues to shrink, with Q4 revenue Decelerating by 4% YoY to $136M. Management noted that facility closures over the past twelve months created a 7% drag on this specific segment. This marks a continued trend of underperformance and portfolio pruning in a division that is failing to keep pace with the broader company.
Technology Deployment for Quality and Safety
To combat the rising tide of liability and quality concerns, Acadia continues to deploy operations-focused technology. Prior mentions of an integrated quality dashboard tracking 50+ KPIs, combined with 24/7 remote patient monitoring and wearable staff safety devices, remain critical tools to justify value to increasingly strict managed Medicaid payers.
Other KPIs
Acadia recorded a staggering $996.2M non-cash goodwill impairment charge and $147.5M in legal settlement expenses (primarily tied to 2019 securities litigation) in Q4. While this largely clears the decks of historical baggage, it decimated the GAAP balance sheet and underscores the cost of past governance and acquisition missteps.
Leverage is Decelerating (worsening). The company exited FY25 with $2.47B in long-term debt and a net leverage ratio of 4.0x adjusted EBITDA, up significantly from earlier in the year. The heavy debt burden directly validates management's emergency pivot toward slashing CapEx in 2026 to preserve liquidity.
Guidance
Decelerating. The midpoint of $3.41B implies just 2.9% YoY growth, a notable step down from the 5.0% growth achieved in FY25. This reflects intentional facility closures, restricted capacity expansion, and Medicaid policy headwinds.
Decelerating. The midpoint implies a 2.7% YoY contraction compared to the $608.9M delivered in FY25. This proves that while management points to top-line stability, structural cost inflation (PLGL, wages) and lost supplemental payments are materially eroding margins.
Decelerating severely. Implies a ~29% drop at the midpoint from FY25's $2.00 per share. This is dragged down by lower expected operating profits and elevated interest expenses on the higher debt load.
Stable. The midpoint of $133.5M is practically flat compared to the $134.2M achieved in 25Q1, indicating that profitability pressures will persist immediately out of the gate in the new fiscal year.
Key Questions
PLGL Reserve Adequacy
You absorbed a $52.7M adjustment to PLGL reserves in Q4, bringing the balance sheet reserve to $153M. What specific actuarial factors drove this spike, and what gives you confidence that this new baseline is adequate to prevent further true-ups in 2026?
Bridge to Same-Facility Growth
Your 2026 guidance assumes 0% to 1% same-facility volume growth, burdened by a 350 bps headwind from New York Medicaid changes. Excluding New York, what are the primary assumptions for core volume growth across the rest of the portfolio?
Path to De-leveraging
With net leverage now at 4.0x and Adjusted EBITDA guided down for 2026, how do you balance the mandatory debt service with the operational requirement to staff and ramp the 1,000+ beds you just opened in 2025?